pentosidine

01/01/2022 - "We previously identified a subtype of schizophrenia (SCZ) characterized by increased plasma pentosidine, a marker of glycation and oxidative stress (PEN-SCZ). "
01/01/2021 - "Previously, we identified a subpopulation of schizophrenia (SCZ) showing increased levels of plasma pentosidine, a marker of glycation and oxidative stress. "
01/01/2020 - "There was a significant negative correlation between plasma pentosidine and white matter integrity in the schizophrenia group, but not in the control group. "
01/01/2017 - "Carbonyl stress in patients with schizophrenia has been reported to be reflected by an increase in peripheral pentosidine levels. "
01/01/2012 - "We found that seventeen schizophrenia (approximately 17.4%) showed increases in plasma pentosidine content although they have no physical complications, and concomitantly marked decrease of pyridoxal levels was found in schizophrenia. "

05/01/1997 - "Skin samples obtained from NIDDM subjects at the beginning of the study had significantly increased levels of glucitolyllysine, pentosidine, and hydroxypyridinium, as compared with age-matched control subjects. "
01/01/2023 - "One hundred and twenty-two patients with type 2 diabetes were grouped by LVEF quartiles to compare the differences between their clinical data and serum pentosidine levels. "
01/01/2018 - "Urinary Pentosidine levels negatively associates with trabecular bone scores in patients with type 2 diabetes mellitus."
10/01/2016 - "The associations between skin autofluorescence and pentosidine, and carotid-femoral pulse-wave velocity were more pronounced in individuals with type 2 diabetes mellitus (P-interaction<0.10). "
05/01/2013 - "We have investigated whether serum AGEs, sRAGE and pentosidine levels were increased and correlated with microvascular complications in type 2 diabetes mellitus (DM). "

11/01/2012 - "Serum levels of AGEs, sRAGE and pentosidine were significantly increased in patients with diabetes mellitus compared to nondiabetic controls (P<.01, P<.001, P<.001 respectively). "
09/01/1997 - "Lens autofluorescence was higher in diabetic than non-diabetic subjects; pentosidine quantities were significantly higher in the diabetic than the non-diabetic group indicating that pentosidine was involved in the greater intensity of autofluorescence in the lenses of patients with diabetes mellitus."
11/01/2021 - "The detection of serum pentosidine levels in clinics might be helpful for the monitoring of type 2 diabetes mellitus complicated with sarcopenia."
11/01/2021 - "Pentosidine is an independent risk factor for sarcopenia in Chinese middle-aged and elderly men with type 2 diabetes mellitus. "
11/01/2021 - "Elevated serum pentosidine is independently associated with the high prevalence of sarcopenia in Chinese middle-aged and elderly men with type 2 diabetes mellitus."

04/01/2005 - "In addition, a period of ten months of acceptable metabolic control is not enough to normalize pentosidine levels in diabetics, thus emphasizing the need for a longer period of improved metabolic control to reduce both this parameter and the burden of chronic diabetic complications."
09/01/1998 - "The present study was undertaken to assess the factors determining plasma total pentosidine level in diabetic patients and the possible relation between plasma pentosidine level and diabetic complications. "
03/19/2011 - "Pentosidine has a pivotal role in diabetic complications, probably as a consequence of the diverse properties of this compound, which alters the structure and function of molecules in biological systems. "
07/01/1993 - "These results demonstrate that urinary pentosidine, especially in free form, could be a useful marker for the assessment of diabetes and diabetic complications."
10/01/1993 - "Pentosidine is an advanced Maillard/glycation reaction product the formation of which in human skin is significantly increased in Type 1 (insulin-dependent) diabetes mellitus and correlates with the severity of diabetic complications. "

01/01/2023 - "Multivariate analysis identified plasma pentosidine levels as a significant and independent factor associated with sarcopenia (odds ratio [OR], 1.07; p = 0.036) and low gait speed (OR, 1.06; p = 0.036), with the cutoff levels of 0.0792 μg/mL (sensitivity/specificity, 0.600/0.773) and 0.0745 μg/mL (sensitivity/specificity, 0.735/0.691), respectively. "
01/01/2023 - "The prevalence of sarcopenia and low gait speed significantly increased stepwise with increasing plasma pentosidine levels, with the highest in the H-Pen group (59.4% [19/32] and 56.3% [18/32], respectively) and lowest in the L-Pen group (18.8% [6/32] and 6.3% [2/32], respectively). "
11/01/2021 - "The association between pentosidine and the prevalence of sarcopenia was still significant after additional adjustments (odds ratio 1.01, P < 0.05). "
11/01/2021 - "The prevalence of sarcopenia increased as the quartile of serum pentosidine increased (P < 0.05). "
11/01/2021 - "Serum pentosidine was significantly higher in the sarcopenia group (191.27 pmol/mL) than in the non-sarcopenia group (34.93 pmol/mL). "